Nishimura Marin, Birgersdotter-Green Ulrika
Division of Cardiovascular Medicine, Department of Medicine, University of California, San Diego, 9500 Gilman Drive, Mail Code 7411, La Jolla, CA 92037-7411, USA.
Pacemaker and ICD Services, Cardiac Electrophysiology Section, Division of Cardiology, Department of Medicine, University of California, San Diego, 9444 Medical Center Drive, MC 7411, La Jolla, CA 92037, USA.
Card Electrophysiol Clin. 2019 Mar;11(1):115-122. doi: 10.1016/j.ccep.2018.11.015.
Cardiac resynchronization therapy (CRT) has been shown to have a multitude of beneficial effects in select patients with systolic heart failure, by enhancing reverse remodeling, improving quality of life and functional status, reducing risk of heart failure admission, and most importantly, improving survival. Although women were underrepresented in the clinical trials, they were demonstrated to derive greater therapeutic benefit from CRT compared with men. Importantly, women were noted to derive benefit at a lesser degree of QRS prolongation than men, well below the now generally accepted cutoff of QRS ≥150 milliseconds.
心脏再同步治疗（CRT）已被证明对某些收缩性心力衰竭患者有多种有益效果，可增强逆向重构、改善生活质量和功能状态、降低心力衰竭住院风险，最重要的是提高生存率。尽管在临床试验中女性的代表性不足，但与男性相比，她们从CRT中获得的治疗益处更大。重要的是，与男性相比，女性在QRS波延长程度较低时就能获益，远低于目前普遍接受的QRS≥150毫秒的临界值。
